ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,221 to 2,240 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
HEART Care vs Usual Care: serious adverse events345 of 1,821

405 of 1,827

-3.2 points

-5.8 to -0.6

3,648NCT01756846

Impact on Management of the HEART Risk Score in Chest Pain Patients

Metformin vs Placebo: serious adverse events1 of 1,816

3 of 1,816

-0.1 points

-0.4 to 0.2

3,632NCT01101438

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Norepinephrine vs Phenylephrine: Rehospitalization Within 30 Days56 of 1,809

66 of 1,817

-0.5 points

-1.7 to 0.6

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: Number of Participants With Myocardial Injury After Non-cardiac Surgery (MINS)44 of 1,809

38 of 1,817

0.3 points

-0.6 to 1.3

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: Number of Participants Who Died Within 30 Days After Surgery20 of 1,809

22 of 1,817

-0.1 points

-0.8 to 0.6

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: Number of Participants With Severe Acute Kidney Injury28 of 1,809

31 of 1,817

-0.2 points

-1.0 to 0.7

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: Number of Participants With Assigned Vasopressor Given1,570 of 1,809

1,627 of 1,817

-2.8 points

-4.9 to -0.7

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: Number of Participants With Acute Kidney Injury (AKI)140 of 1,809

135 of 1,817

0.3 points

-1.4 to 2.0

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: deaths from any cause20 of 1,809

22 of 1,817

-0.1 points

-0.8 to 0.6

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: Adverse Cardio-renal Events168 of 1,809

159 of 1,817

0.5 points

-1.3 to 2.4

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Norepinephrine vs Phenylephrine: serious adverse events20 of 1,809

22 of 1,817

-0.1 points

-0.8 to 0.6

3,626NCT04789330

Norepinephrine vs Phenylephrine During General Anesthesia

Canadian C-Spine Rule vs Control Phase (Usual Care): Proportion of Patients Transported With Spinal Immobilization813 of 1,885

1,334 of 1,740

-33.5 points

-36.5 to -30.5

3,625NCT02786966

A Pragmatic Evaluation of the Canadian C-Spine Rule by Paramedics

Intervention Group vs Wait List Control Group: Sustainability of the Intervention Benefit for Completion of the HPV Vaccine.1,279 of 2,211

703 of 1,410

8.0 points

4.7 to 11.3

3,621NCT04180462

Increasing Optimal Use of HPV Vaccination in Primary Care

Intervention Group vs Wait List Control Group: Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine.1,812 of 2,211

1,052 of 1,410

7.3 points

4.6 to 10.1

3,621NCT04180462

Increasing Optimal Use of HPV Vaccination in Primary Care

aCRT ON vs aCRT OFF: Percent of Patients With Interventions for Heart Failure Decompensation238 of 1,810

255 of 1,807

-1.0 points

-3.2 to 1.3

3,617NCT02205359

AdaptResponse Clinical Trial

aCRT ON vs aCRT OFF: All-cause Mortality293 of 1,810

327 of 1,807

-1.9 points

-4.4 to 0.5

3,617NCT02205359

AdaptResponse Clinical Trial

aCRT ON vs aCRT OFF: Atrial Fibrillation317 of 1,810

316 of 1,807

0.0 points

-2.5 to 2.5

3,617NCT02205359

AdaptResponse Clinical Trial

aCRT ON vs aCRT OFF: deaths from any cause293 of 1,810

327 of 1,807

-1.9 points

-4.4 to 0.5

3,617NCT02205359

AdaptResponse Clinical Trial

aCRT ON vs aCRT OFF: Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation430 of 1,810

470 of 1,807

-2.3 points

-5.1 to 0.6

3,617NCT02205359

AdaptResponse Clinical Trial

aCRT ON vs aCRT OFF: serious adverse events1,072 of 1,810

1,073 of 1,807

-0.2 points

-3.4 to 3.0

3,617NCT02205359

AdaptResponse Clinical Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=112"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=112

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01756846-sae",
        "title": "HEART Care vs Usual Care: serious adverse events",
        "summary": "345 of 1821 against 405 of 1827; risk difference -3.2 points, 95% interval -5.8 to -0.6; NCT01756846, Impact on Management of the HEART Risk Score in Chest Pain Patients",
        "record": "/library/comparisons/NCT01756846-sae",
        "nct_id": "NCT01756846",
        "kind": "serious-adverse-events",
        "participants": 3648,
        "risk_difference": {
          "value": -0.03221853417842738,
          "lower": -0.05840101329420018,
          "upper": -0.005986831314517525
        },
        "group_1": "345 of 1,821",
        "group_2": "405 of 1,827",
        "difference": "-3.2 points",
        "interval": "-5.8 to -0.6",
        "trial_title": "Impact on Management of the HEART Risk Score in Chest Pain Patients"
      },
      {
        "id": "NCT01101438-sae",
        "title": "Metformin vs Placebo: serious adverse events",
        "summary": "1 of 1816 against 3 of 1816; risk difference -0.1 points, 95% interval -0.4 to 0.2; NCT01101438, A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer",
        "record": "/library/comparisons/NCT01101438-sae",
        "nct_id": "NCT01101438",
        "kind": "serious-adverse-events",
        "participants": 3632,
        "risk_difference": {
          "value": -0.0011013215859030836,
          "lower": -0.004327254854396716,
          "upper": 0.0016829110282150705
        },
        "group_1": "1 of 1,816",
        "group_2": "3 of 1,816",
        "difference": "-0.1 points",
        "interval": "-0.4 to 0.2",
        "trial_title": "A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=113",
  "request_id": "cwH05gU7HJC1Zw--"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?